Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series

Background: Borderline personality disorder (BPD) is a heterogeneous and highly comorbid disorder. Suicidality, aggression and substance abuse are common presentations of BPD. Our case series is the first to highlight the role of brexpiprazole in improving these symptoms in patients with BPD. Case p...

Full description

Saved in:
Bibliographic Details
Main Authors: Francis, Benedict, Ganasan, Vijay, Sulaiman, Abdul Rasyid
Format: Article
Published: MDPI 2024
Subjects:
Online Access:http://eprints.um.edu.my/45679/
https://doi.org/10.3390/medicina60020283
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.eprints.45679
record_format eprints
spelling my.um.eprints.456792024-11-08T07:04:52Z http://eprints.um.edu.my/45679/ Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series Francis, Benedict Ganasan, Vijay Sulaiman, Abdul Rasyid R Medicine (General) Mental healing Background: Borderline personality disorder (BPD) is a heterogeneous and highly comorbid disorder. Suicidality, aggression and substance abuse are common presentations of BPD. Our case series is the first to highlight the role of brexpiprazole in improving these symptoms in patients with BPD. Case presentation: We describe three cases demonstrating the role of brexpiprazole in improving BPD's prominent features and comorbidities. All cases improved when brexpiprazole was added to their treatment regime. Case 1: A 26-year-old woman who was diagnosed with BPD and cyclothymia, presented to the psychiatric emergency unit with impulsive suicidal behaviour. Case 2: A 43-year-old woman suffering from BPD sought help due to her violent behaviour and emotional dysregulation. Case 3: A 22-year-old woman with underlying attention deficit and hyperactivity disorder, polysubstance use disorder and BPD presented with dysregulated emotions. Conclusions: Our case series provides anecdotal evidence of the potential role of brexpiprazole in attenuating suicidality, aggression and substance abuse in patients with BPD. We postulate that brexpiprazole's high affinity for the 5HT1A/5HT2A receptors, coupled with its low intrinsic effect on the D2/D3 receptor system, is fundamental in its actions to stabilise the aberrant dopaminergic and serotonergic signalling in BPD. Future research should focus on well-designed clinical trials investigating the efficacy of brexpiprazole in patients with BPD. MDPI 2024-02 Article PeerReviewed Francis, Benedict and Ganasan, Vijay and Sulaiman, Abdul Rasyid (2024) Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series. Medicina-Lithuania, 60 (2). p. 283. ISSN 1010-660X, DOI https://doi.org/10.3390/medicina60020283 <https://doi.org/10.3390/medicina60020283>. https://doi.org/10.3390/medicina60020283 10.3390/medicina60020283
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
topic R Medicine (General)
Mental healing
spellingShingle R Medicine (General)
Mental healing
Francis, Benedict
Ganasan, Vijay
Sulaiman, Abdul Rasyid
Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series
description Background: Borderline personality disorder (BPD) is a heterogeneous and highly comorbid disorder. Suicidality, aggression and substance abuse are common presentations of BPD. Our case series is the first to highlight the role of brexpiprazole in improving these symptoms in patients with BPD. Case presentation: We describe three cases demonstrating the role of brexpiprazole in improving BPD's prominent features and comorbidities. All cases improved when brexpiprazole was added to their treatment regime. Case 1: A 26-year-old woman who was diagnosed with BPD and cyclothymia, presented to the psychiatric emergency unit with impulsive suicidal behaviour. Case 2: A 43-year-old woman suffering from BPD sought help due to her violent behaviour and emotional dysregulation. Case 3: A 22-year-old woman with underlying attention deficit and hyperactivity disorder, polysubstance use disorder and BPD presented with dysregulated emotions. Conclusions: Our case series provides anecdotal evidence of the potential role of brexpiprazole in attenuating suicidality, aggression and substance abuse in patients with BPD. We postulate that brexpiprazole's high affinity for the 5HT1A/5HT2A receptors, coupled with its low intrinsic effect on the D2/D3 receptor system, is fundamental in its actions to stabilise the aberrant dopaminergic and serotonergic signalling in BPD. Future research should focus on well-designed clinical trials investigating the efficacy of brexpiprazole in patients with BPD.
format Article
author Francis, Benedict
Ganasan, Vijay
Sulaiman, Abdul Rasyid
author_facet Francis, Benedict
Ganasan, Vijay
Sulaiman, Abdul Rasyid
author_sort Francis, Benedict
title Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series
title_short Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series
title_full Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series
title_fullStr Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series
title_full_unstemmed Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series
title_sort brexpiprazole attenuates aggression, suicidality and substance use in borderline personality disorder: a case series
publisher MDPI
publishDate 2024
url http://eprints.um.edu.my/45679/
https://doi.org/10.3390/medicina60020283
_version_ 1816130437792137216
score 13.226641